16.03.2017
BB BIOTECH AG CH0038389992
DGAP-News: BB Biotech AG: Shareholders at the general meeting vote in favor of all proposals and approve the dividend of CHF 2.75
DGAP-News: BB BIOTECH AG / Key word(s): AGM/EGM/Dividend
BB Biotech AG: Shareholders at the general meeting vote in favor of all
proposals and approve the dividend of CHF 2.75 (news with additional
features)
16.03.2017 / 17:35
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
Media Release of March 16, 2017
BB Biotech AG: Shareholders at the general meeting vote in favor of all
proposals and approve the dividend of CHF 2.75
All proposals of BB Biotech AG's Board of Directors were approved by
shareholders at its Annual General Meeting held today.
Shareholders voted in favor of the proposal to pay out a dividend of CHF
2.75 per share. Payment will be made on March 22, 2017, the date of record
is March 21, 2017 and the ex-dividend date is March 20, 2017.
Shareholders elected the previous board members Dr. Erich Hunziker,
Chairman, Dr. Clive Meanwell and Prof. Dr. Dr. Klaus Strein to another
one-year term of office.
Investor Relations
Bellevue Asset Management AG, Seestrasse 16, 8700 Küsnacht, Switzerland,
Tel. +41 44 267 67 00
Dr. Silvia Schanz, [email protected]
Maria-Grazia Iten-Alderuccio, [email protected]
Claude Mikkelsen, [email protected]
Media Relations
Bellevue Asset Management AG, Seestrasse 16, 8700 Küsnacht, Switzerland,
Tel. +41 44 267 67 00
Tanja Chicherio, [email protected]
b-public AG, Pfingstweidstrasse 6, 8005 Zurich, Switzerland, Tel. +41 79 423
22 28
Thomas Egger, [email protected]
www.bbbiotech.com
Company profile
BB Biotech invests in companies in the fast growing market of biotechnology
and is one of the world's largest investors in this sector. BB Biotech is
listed in Switzerland, Germany and Italy. Its investments are focused on
listed companies that are developing and commercializing novel medical
treatments and cures. BB Biotech's investment selection process is guided by
the fundamental research and analysis of physicians and molecular
biologists. Its Board of Directors has many years of experience in industry
and science.
Disclaimer
This release contains forward-looking statements and expectations as well as
assessments, beliefs and assumptions. Such statements are based on the
current expectations of BB Biotech, its directors and officers, and are,
therefore, subject to risks and uncertainties that may change over time. As
actual developments may significantly differ, BB Biotech and its directors
and officers accept no responsibility in that regard. All forward-looking
statements included in this release are made only as of the date of this
release and BB Biotech and its directors and officers assume no obligation
to update any forward-looking statements as a result of new information,
future events or other factors.
---------------------------------------------------------------------------
Additional features:
Document: http://n.eqs.com/c/fncls.ssp?u=DMABCASLQD
Document title: Media release
---------------------------------------------------------------------------
16.03.2017 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: BB BIOTECH AG
Schwertstrasse 6
8200 Schaffhausen
Switzerland
Phone: +41 52 624 08 45
E-mail: [email protected]
Internet: www.bbbiotech.ch
ISIN: CH0038389992
WKN: A0NFN3
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated
Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover,
Munich, Stuttgart; SIX
End of News DGAP News Service
---------------------------------------------------------------------------
554589 16.03.2017
|
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu
BB BIOTECH AG ISIN: CH0038389992 können Sie bei EQS abrufen
Biotechnologie , A0NFN3 , BBZA , XETR:BBZA